等渗平衡液与0.9%氯化钠用于中重度创伤性颅脑损伤患者的比较:一项双盲随机对照试验
这项双盲随机对照试验在马来亚大学医学中心纳入70例18至65岁中重度创伤性颅脑损伤患者,随机接受0.9%氯化钠(NS组38例)或Sterofundin(SF组32例)治疗72小时。主要终点院内死亡率NS组3例(7.9%)vs SF组4例(12.5%),RR=1.29(95%CI 0.64至2.59;p=0.695),无显著差异。SF组第3天颅内压显著高于NS组(18.60±9.26 vs 12.77±3.63;95%CI -11.46至0.20;p=0.037)。两组均无患者发生急性肾损伤或需要肾脏替代治疗,3天生化指标、脑灌注压、无呼吸机天数、ICU住院时间及6个月GOS-E评分均无显著差异。
要点
- 中重度TBI患者使用SF与NS相比,院内死亡率无显著差异:NS组3例(7.9%)vs SF组4例(12.5%),RR=1.29(95%CI 0.64至2.59;p=0.695)。
- SF组第3天颅内压显著高于NS组:18.60±9.26 vs 12.77±3.63(95%CI -11.46至0.20;p=0.037)。
- 两组均无患者发生急性肾损伤或需要肾脏替代治疗。
- 3天生化指标、脑灌注压、无呼吸机天数、ICU住院时间及6个月GOS-E评分在两组间均无显著差异。
- 研究共纳入70例患者,NS组38例,SF组32例,液体治疗持续72小时。
适用人群与场景
- 年龄18至65岁的中重度创伤性颅脑损伤患者,在马来亚大学医学中心住院治疗。
处置流程与药物剂量
- 研究液体(0.9%氯化钠或Sterofundin)以持续输注或推注方式给药72小时。
研究设计与关键结果
- 双盲随机对照试验,共纳入70例中重度TBI患者,NS组38例,SF组32例,在马来亚大学医学中心于2017年2月至2019年11月进行。
- 主要终点院内死亡率:NS组3例(7.9%)vs SF组4例(12.5%),RR=1.29(95%CI 0.64至2.59;p=0.695)。
- 第3天颅内压:SF组18.60±9.26 vs NS组12.77±3.63(95%CI -11.46至0.20;p=0.037),SF组显著更高。
- 两组均无患者发生急性肾损伤或需要肾脏替代治疗。
- 3天生化指标、脑灌注压、无呼吸机天数、ICU住院时间及6个月GOS-E评分在两组间均无显著差异。
证据类型、等级与局限
- 证据类型:双盲随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在中重度TBI患者中,使用SF与NS相比未降低院内死亡率、未减少急性肾损伤发生、未改善6个月GOS-E评分。
- 作者认为,与NS相比,SF的使用与院内死亡率降低、急性肾损伤发生或6个月GOS-E改善无关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND IMPORTANCE: Traumatic brain injury (TBI) is a global health concern with significant economic impact. Optimal fluid therapy aims to restore intravascular volume, maintain cerebral perfusion pressure and blood flow, thus preventing secondary brain injury. While 0.9% saline (NS) is commonly used, concerns about acid-base and electrolyte imbalance and development of acute kidney injury (AKI) lead to consideration of balanced fluids as an alternative.
OBJECTIVES: This study aimed to compare the outcomes of patients with moderate to severe TBI treated with Sterofundin (SF) versus NS.
DESIGN, SETTINGS AND PARTICIPANTS: A double-blinded randomised controlled trial of patients aged 18 to 65 years with TBI was conducted at the University Malaya Medical Centre from February 2017 to November 2019.
INTERVENTION OR EXPOSURE: Patients were randomly assigned to receive either NS or SF. The study fluids were administered for 72 h as continuous infusions or boluses. Participants, investigators, and staff were blinded to the fluid type.
OUTCOMES MEASURE AND ANALYSIS: The primary outcome was in-hospital mortality. Relative risk (RR) with 95% confidence interval (CI) was calculated.
MAIN RESULTS: A total of 70 patients were included in the analysis, with 38 in the NS group and 32 in the SF group. The in-hospital mortality rate were 3 (7.9%) in the NS group vs. 4 (12.5%) in the SF group, RR = 1.29 (95% CI, 0.64 to 2.59; p = 0.695). No patients developed AKI and required renal replacement therapy. ICP on day 3 was significantly higher in the SF group (18.60 ± 9.26) compared to 12.77 ± 3.63 in the NS group, (95% CI, -11.46 to 0.20; p = 0.037). There were no significant differences in 3-day biochemical parameters and cerebral perfusion pressure, ventilator-free days, length of ICU stay, or Glasgow Outcome Scale-Extended (GOS-E) score at 6 months.
CONCLUSIONS: In patients with moderate to severe TBI, the use of SF was not associated with reduced in-hospital mortality, development of AKI, or improved 6-month GOS-E when compared to NS.
参考来源
- Poh K, Bustam A, Hasan MS, et al. Isotonic balanced fluid versus 0.9% saline in patients with moderate to severe traumatic brain injury: A double-blinded randomised controlled trial. Am J Emerg Med. 2023. PMID: 38118385. doi:10.1016/j.ajem.2023.11.064
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。